Levosimendan Zentiva

Levosimendan, the active ingredient in Levosimendan Zentiva, is a calcium sensitizer presented as an intravenous solution for intravenous use. It improves cardiac contractility and reduces vascular resistance, and is indicated for the treatment of acute decompensated heart failure in adult patients.

GNH USA supplies Levosimendan Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution, ensuring product integrity and traceability.

Levosimendan is used in the management of acute heart failure syndromes by enhancing myocardial contractility and reducing afterload.

Acute decompensated heart failure: improves cardiac output and relieves symptoms in hospitalized patients. Cardiogenic shock: provides hemodynamic support when conventional therapies are insufficient. Severe left ventricular dysfunction: enhances contractility to stabilize patients awaiting further intervention.

Levosimendan may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Hypotension: drop in blood pressure, especially after rapid infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Arrhythmia: ventricular or atrial ectopic beats.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion. - Anaphylactic reaction: rare but potentially life‑threatening hypersensitivity.

When using Levosimendan, clinicians should observe specific safety measures to minimize risk. - Monitor blood pressure: watch for symptomatic hypotension during and after infusion. - Assess cardiac rhythm: observe for new or worsening arrhythmias. - Use with caution in renal impairment: adjust monitoring as drug clearance may be affected. - Avoid in severe hepatic dysfunction: risk of drug accumulation and heightened effects. - Contraindicated in patients with known hypersensitivity to levosimendan or its excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with other medications, influencing hemodynamic stability or drug metabolism.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilatory effect may cause profound hypotension. - Other vasodilators (e.g., nitroglycerin): risk of severe blood pressure fall. - Beta‑blockers: may blunt the inotropic response of levosimendan.

Moderate Interactions (Monitor Closely): - Loop diuretics: may exacerbate electrolyte disturbances and affect renal function. - ACE inhibitors or ARBs: combined effect on blood pressure requires careful titration.